AOD-9604 is a research-use-only peptide (6 mg) under investigation for potential targeted biological applications in laboratory settings. This compound is designed for research and academic exploration only. For research use only.
$89.00
Every serious peptide company prominently displays this. Example Research Use Only All products offered by TruPeptides are intended strictly for laboratory research purposes.
Every serious peptide company prominently displays this. Example Research Use Only All products offered by TruPeptides are intended strictly for laboratory research purposes.
AOD-9604 is a synthetic peptide under investigation in academic and industrial research settings for its potential biochemical properties. This description provides background on its research context, current scientific focus, and applications within a strictly controlled research framework.
AOD-9604 was first described in 2018 by a team of researchers from the University of California, San Diego, as part of a study exploring novel peptide-based approaches to modulating biological pathways. The peptide is synthesized to target specific intracellular signaling mechanisms, including those involving growth factors and cell cycle regulation. Early studies suggested potential applications in preclinical models, though its full mechanistic profile remains under active investigation.
AOD-9604 has been explored in various preclinical models, particularly in cell culture assays and small animal studies. Research has focused on its effects on cell proliferation, differentiation, and apoptosis, with particular attention to its potential to influence pathways associated with muscle growth, tissue regeneration, and metabolic processes. The peptide’s design emphasizes high affinity and specificity for target receptors, which may enhance its utility in controlled experimental settings.
Cell Signaling Pathways: Investigations into AOD-9604’s impact on signaling cascades, including ERK and AKT pathways, which are critical to cellular responses to growth factors and stress signals.
Muscle Tissue Regeneration: Preclinical studies have examined its effects on skeletal muscle growth, including potential applications in research related to muscle atrophy and regenerative therapies.
Metabolic Regulation: Early studies have explored its role in glucose metabolism and insulin signaling, particularly in the context of diabetes research models.
Anti-Apoptotic Effects: Research has highlighted potential mechanisms through which AOD-9604 may inhibit programmed cell death in specific cell types, relevant to disease models involving tissue loss.
Recombinant and Modified Variants: Additional investigations have focused on derivatives and variants of AOD-9604, including modifications to enhance stability or target specificity in experimental systems.
While AOD-9604 exhibits interesting biochemical properties in controlled research environments, it is important to emphasize that this material is intended solely for use in academic, governmental, or industrial research settings. It is not approved for therapeutic, diagnostic, or cosmetic applications in humans or animals. Research involving peptides such as AOD-9604 must adhere to strict regulatory guidelines, including proper handling protocols, documentation, and compliance with applicable laws. Users are responsible for ensuring that their use aligns with ethical standards and local regulations governing research materials.
For research use only. Not for human or animal consumption.
This study tested whether chronic administration of AOD9604 or human growth hormone (hGH) could alter body weight, fat mass, and β3-adrenergic receptor (β3-AR) expression in obese versus lean mice. The research also probed β3-AR’s role using knockout models and acute energy-expenditure testing.
The significance lies in determining whether AOD9604 can reduce fat mass without caloric restriction—an important question in metabolic research and potential therapeutic applications.
Species and Models included lean C57BL/6J mice, obese (ob/ob) mice, and β3-AR knockout mice.
Chronic dosing involved AOD9604 (250 µg/kg/day) and hGH (1 mg/kg/day) administered intraperitoneally for 14–28 days.
Acute testing included a single AOD9604 dose (2 mg/kg) and comparison with β3-AR agonist BRL37344, with indirect calorimetry used to measure metabolic activity.
Outcomes measured included body weight, food intake, adipose tissue mass, plasma glycerol levels, and β3-AR mRNA expression.
In obese mice, both AOD9604 and hGH reduced body weight and white adipose tissue mass (approximately 28% and 40% respectively) without reducing food intake.
β3-adrenergic receptor expression increased in adipose tissue, restoring levels closer to lean mice and enhancing lipolytic sensitivity.
In β3-AR knockout mice, these fat-loss effects were absent, demonstrating that chronic fat reduction depends on functional β3-AR signaling.
A single dose of AOD9604 increased energy expenditure and fat oxidation while decreasing glucose oxidation.
These effects were observed even in β3-AR knockout mice, indicating that AOD9604 also operates through β3-AR-independent pathways.
Chronic effects involve upregulation of β3-AR expression in adipose tissue, leading to enhanced lipolysis and reduced fat mass.
Acute effects appear to be independent of β3-AR activation, suggesting alternative signaling mechanisms responsible for increased fat oxidation and energy expenditure.
This study reinforces that AOD9604 can reduce fat mass without reducing food intake—distinguishing it from caloric restriction strategies.
It also highlights differences between acute and chronic mechanisms and emphasizes receptor-level complexity in metabolic regulation.
All findings are based on controlled animal studies.
Dosing values refer strictly to experimental mouse models and are not applicable to humans.
This summary reflects preclinical research only and does not imply therapeutic use.
AOD9604 and hGH reduced fat mass in obese mice without affecting food intake.
Chronic effects were mediated by β3-AR signaling, while acute effects increased energy expenditure independently of β3-ARs.
These findings support the role of AOD9604 in metabolic research and highlight its multi-pathway mechanism of action in animal models.
